Physician profile
James E Renehan
NPI 1386607117
$7,128.64
in general payments reported to CMS, 2019-2025
45 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $915 · 2021: $1,148 · 2022: $892 · 2023: $730 · 2024: $1,028 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,789.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,089.87 | 2019-2025 | Veozah, Myrbetriq, Xtandi |
| Abbvie INC. | $531.42 | 2019-2025 | |
| Pfizer INC. | $506.33 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $375.23 | 2019-2024 | Edex, Xiaflex, Aveed |
| Allergan, INC. | $352.22 | 2019-2022 | |
| Boston Scientific Corporation | $330.73 | 2019-2025 | Axonics, Ams 700, Spaceoar Vue System - 10ml |
| Amgen INC. | $314.46 | 2019-2024 | Prolia |
| Sumitomo Pharma America, INC. | $305.79 | 2023-2025 | Gemtesa, Orgovyx |
| Olympus America INC. | $277.64 | 2020-2025 | Itind System |
| Coloplast Corp | $264.42 | 2019-2022 | |
| Janssen Biotech, INC. | $245.21 | 2019-2025 | Erleada, Akeega |
| Tolmar Pharmaceuticals, INC. | $214.66 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $210.02 | 2019-2025 | Provenge |
| Axonics, INC. | $189.01 | 2020-2024 | Axonics, Bulkamid |
| Procept Biorobotics Corporation | $169.50 | 2024 | Aquabeam System |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Renehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.